Targeting of αvβ3 in tumor tissues is complex due to the dose-dependent opposing effects of the inhibitor: low doses of RGD-peptides have been reported to stimulate VEGF-blood vessel growth and tumor angiogenesis (42), in contrast with inhibition at higher doses (36). Here, VEGFA is linked to neoplasm.